Physician profile
Jason Wellen
NPI 1134331382
$617,420.28
in general payments reported to CMS, 2019-2025
15 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $41K · 2021: $51K · 2022: $105K · 2023: $77K · 2024: $129K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Education: $84K · Consulting Fee: $66K · Travel and Lodging: $48K · Food and Beverage: $8,161 · Grant: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,491.00 |
| Education | $84,080.00 |
| Consulting Fee | $66,400.04 |
| Travel and Lodging | $47,756.31 |
| Food and Beverage | $8,160.67 |
| Grant | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $186,690.65 | 2020-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Sanofi-Aventis U.S. LLC | $134,087.13 | 2020-2025 | |
| Veloxis Pharmaceuticals, INC. | $121,905.66 | 2019-2023 | Envarsus |
| Baxter Healthcare | $46,094.20 | 2019-2024 | Tisseel, Floseal, Perclot |
| Genzyme Corporation | $33,808.58 | 2019-2022 | |
| Medical Device Business Services, INC. | $20,091.81 | 2023-2025 | Prolene |
| Ethicon Endo-Surgery INC. | $18,850.65 | 2024-2025 | Prolene |
| Ethicon US, LLC | $17,313.74 | 2022-2025 | Prolene |
| E.R. Squibb & Sons, L.L.C. | $16,535.70 | 2019 | |
| Ethicon INC. | $11,615.00 | 2025 | Prolene |
| Abbvie INC. | $5,495.50 | 2023-2024 | Strattice Reconstructive Tissue Matrix Bps |
| Allergan, INC. | $3,597.46 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,171.44 | 2019 | |
| United Therapeutics Corporation | $127.07 | 2024 | Tyvaso, Steen Solution |
| Boston Scientific Corporation | $35.69 | 2025 | Iceforce 2.1 Cx 90 Cryoablation Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wellen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.